News
TYRX, Inc. raises $20 million in private financing
Download the PDF
December 8, 2010
TYRX AIGISRx® antibacterial envelope shows low infection rate and high implantation success for CIED procedures
Download the PDF
October 19, 2010
FDA provides clearance of TyRx antibacterial patch for soft tissue repair
Download the PDF
April 27, 2010
TyRx announces commercial release of the AIGISRx™ Flat
Download the PDF
April 13, 2010
TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements
Download the PDF
March 24, 2010
TyRx
Monmouth Junction, NJ
TyRx is a medical device company developing a range of drug-eluting implantable devices based on proprietary tyrosine polymer technology licensed from Rutgers University. The company's lead product is AIGIS-Rx™, an antibiotic-eluting mesh envelope into which pacemakers and defibrillators can be inserted prior to surgical implantation, thereby reducing the risk of post-procedure infection.